Luminex Co. (NASDAQ:LMNX) – Investment analysts at Jefferies Financial Group lowered their Q4 2019 earnings per share (EPS) estimates for Luminex in a research report issued to clients and investors on Wednesday, February 6th. Jefferies Financial Group analyst B. Couillard now anticipates that the medical instruments supplier will earn $0.13 per share for the quarter, down from their prior estimate of $0.19.
Luminex (NASDAQ:LMNX) last announced its quarterly earnings data on Monday, February 4th. The medical instruments supplier reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.08). Luminex had a net margin of 5.81% and a return on equity of 4.61%. The firm had revenue of $81.10 million during the quarter, compared to analyst estimates of $80.76 million. During the same period in the prior year, the company posted $0.20 earnings per share. The firm’s revenue for the quarter was up 3.7% on a year-over-year basis.
LMNX has been the topic of a number of other research reports. ValuEngine downgraded Luminex from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 21st. TheStreet downgraded Luminex from a “b-” rating to a “c+” rating in a research note on Friday, December 14th. BidaskClub upgraded Luminex from a “hold” rating to a “buy” rating in a research note on Wednesday, October 17th. Zacks Investment Research downgraded Luminex from a “hold” rating to a “sell” rating in a research note on Friday, January 18th. Finally, Citigroup lowered their target price on Luminex from $34.00 to $33.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 6th. One research analyst has rated the stock with a sell rating, four have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $28.40.
Shares of LMNX opened at $24.86 on Monday. Luminex has a 52 week low of $18.62 and a 52 week high of $35.37. The stock has a market capitalization of $1.10 billion, a PE ratio of 51.79, a P/E/G ratio of 5.62 and a beta of 0.81.
The business also recently announced a quarterly dividend, which will be paid on Thursday, April 11th. Stockholders of record on Thursday, March 21st will be paid a $0.06 dividend. The ex-dividend date of this dividend is Wednesday, March 20th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.97%. Luminex’s payout ratio is 50.00%.
Several institutional investors and hedge funds have recently modified their holdings of LMNX. Quantamental Technologies LLC purchased a new position in Luminex during the fourth quarter worth approximately $100,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. purchased a new position in Luminex during the fourth quarter worth approximately $100,000. LS Investment Advisors LLC purchased a new position in Luminex during the fourth quarter worth approximately $127,000. Campbell & CO Investment Adviser LLC purchased a new position in Luminex during the third quarter worth approximately $227,000. Finally, People s United Financial Inc. purchased a new position in Luminex during the third quarter worth approximately $238,000. Hedge funds and other institutional investors own 84.29% of the company’s stock.
Luminex Company Profile
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.
Read More: Do You Need a Fiduciary?
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.